Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$0.59.

  • Lipocine's EPS (Basic) fell 4390.24% to -$0.59 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.76, marking a year-over-year decrease of 13783.78%. This contributed to the annual value of -$0.0 for FY2024, which is 9994.67% up from last year.
  • Lipocine's EPS (Basic) amounted to -$0.59 in Q3 2025, which was down 4390.24% from -$0.41 recorded in Q2 2025.
  • Lipocine's 5-year EPS (Basic) high stood at $0.66 for Q1 2024, and its period low was -$1.26 during Q3 2023.
  • For the 5-year period, Lipocine's EPS (Basic) averaged around -$0.31, with its median value being -$0.41 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 33333.33% in 2021, then plummeted by 175000.0% in 2023.
  • Quarter analysis of 5 years shows Lipocine's EPS (Basic) stood at $0.14 in 2021, then tumbled by 407.14% to -$0.43 in 2022, then grew by 2.33% to -$0.42 in 2023, then skyrocketed by 179.32% to $0.33 in 2024, then crashed by 277.11% to -$0.59 in 2025.
  • Its last three reported values are -$0.59 in Q3 2025, -$0.41 for Q2 2025, and -$0.35 during Q1 2025.